Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT02256852 | Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer | completed | Phase 2 | 6 | Qu Biologics Inc.INDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01985113 | Correlation Research of Thioredoxin Reductase in Lung Cancer(TRCRLC) | completed | — | 165 | Hunan Province Tumor HospitalOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01991418 | Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) | completed | — | 165 | Hunan Province Tumor HospitalOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00035516 | A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy | completed | Phase 2 | — | R-PharmINDUSTRY | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT00423449 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | completed | Phase 1 | 61 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT00579683 | Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer | completed | — | 228 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01372384 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT01836679 | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 202 | SCRI Development Innovations, LLCOTHER | 1 | Jan 29, 2016 | clinicaltrials |
| NCT01022671 | Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy | completed | Phase 2 | 52 | Chong Kun Dang PharmaceuticalINDUSTRY | 0 | Jan 28, 2016 | clinicaltrials |
| NCT01326767 | Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring(CEPAC-TDM) | completed | Phase 3 | 366 | Central European Society for Anticancer Drug ResearchOTHER | 2 | Jan 27, 2016 | clinicaltrials |
| NCT01137968 | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 116 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT01823094 | CTP Imaging of Lung Cancer(CTPLC) | completed | — | 14 | University of California, DavisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00130780 | Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC | completed | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02595450 | A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer | completed | — | 299 | Hoffmann-La RocheINDUSTRY | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00588445 | Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01684111 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)(VENUS-1) | completed | Phase 1 | 7 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00349219 | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer(TORCH) | completed | Phase 3 | 760 | National Cancer Institute, NaplesOTHER | 2 | Jan 15, 2016 | clinicaltrials |
| NCT00534027 | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 172 | AmgenINDUSTRY | 0 | Jan 14, 2016 | clinicaltrials |
| NCT00779389 | Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family | completed | Phase 1 | 58 | University of PittsburghOTHER | 1 | Jan 13, 2016 | clinicaltrials |
| NCT02000531 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | completed | Phase 4 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01874678 | A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer | completed | N/A | 45 | TTY BiopharmINDUSTRY | 1 | Jan 12, 2016 | clinicaltrials |
| NCT02038413 | State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients(Lung stage I) | completed | — | 25 | Maastricht Radiation OncologyOTHER | 1 | Jan 12, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT02645318 | Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer | completed | — | 95 | Peking University People's HospitalOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01664533 | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy(TIME) | completed | — | 57 | Hoffmann-La RocheINDUSTRY | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00112294 | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 755 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT01109524 | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 3 | Dec 24, 2015 | clinicaltrials |
| NCT00762034 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 21, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT00883779 | A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 3 | 451 | Hoffmann-La RocheINDUSTRY | 7 | Dec 14, 2015 | clinicaltrials |
| NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | completed | Phase 2 | 37 | Oncolytics BiotechINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT01482182 | Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy | completed | — | 35 | Samsung Medical CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00157209 | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | completed | Phase 2 | 171 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01204697 | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | completed | Phase 2 | 74 | Hoffmann-La RocheINDUSTRY | 1 | Nov 16, 2015 | clinicaltrials |
| NCT01535729 | An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | — | 465 | Hoffmann-La RocheINDUSTRY | 1 | Oct 29, 2015 | clinicaltrials |
| NCT00112346 | Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 120 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00162318 | A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00207116 | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma | completed | Phase 1 | 120 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00965731 | Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer | completed | Phase 1 | 27 | PfizerINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01121575 | A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | completed | Phase 1 | 70 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01924195 | Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） | completed | Phase 2 | 117 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00960115 | Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | completed | Phase 1 / Phase 2 | 178 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 21, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Feb 22, 2016source: clinicaltrials